{"filing":{"accession_number":"0001683168-26-007126","cik":"0000882291","ticker":"AEMD","company_name":"AETHLON MEDICAL INC","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-11","primary_document":"aethlon_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316826007126/aethlon_8k.htm"},"events":[{"id":33497,"run_id":30799,"accession_number":"0001683168-26-007126","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The disclosure describes amendments to employment agreements for the CEO/CFO (James B. Frakes) and Chief Medical Officer (Steven P. LaRosa) that modify severance and health care continuation payment terms in a change-of-control scenario. These amendments alter the timing and structure of compensatory arrangements (converting installment payments to lump sums) without changing the underlying severance amounts, which is a classic compensatory arrangement modification under Item 5.02(e). The amendments are material because they affect the financial obligations owed to named executives upon a triggering event.","company_name":"AETHLON MEDICAL INC","ticker":"AEMD","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36956,"accession_number":"0001683168-26-007126","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes amendments to employment agreements for the CEO/CFO (James B. Frakes) and Chief Medical Officer (Steven P. LaRosa) that modify severance and health care continuation payment terms in a change-of-control scenario. These amendments alter the timing and structure of compensatory arrangements (converting installment payments to lump sums) without changing the underlying severance amounts, which is a classic compensatory arrangement modification under Item 5.02(e). The amendments are material because they affect the financial obligations owed to named executives upon a triggering event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:20:10.681466+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36956,"accession_number":"0001683168-26-007126","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes amendments to employment agreements for the CEO/CFO (James B. Frakes) and Chief Medical Officer (Steven P. LaRosa) that modify severance and health care continuation payment terms in a change-of-control scenario. These amendments alter the timing and structure of compensatory arrangements (converting installment payments to lump sums) without changing the underlying severance amounts, which is a classic compensatory arrangement modification under Item 5.02(e). The amendments are material because they affect the financial obligations owed to named executives upon a triggering event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:20:10.681466+00:00","company_name":"AETHLON MEDICAL INC","ticker":"AEMD","filing_date":"2026-09-15"}]}